Objective To compare the benefits and harms of drug treatments for adults with type 2 diabetes, adding non-steroidal mineralocorticoid receptor antagonists (including finerenone) and tirzepatide (a dual glucose dependent insulinotropic polypeptide (GIP)/glucagon-like peptide-1 (GLP-1) receptor agonist) to previously existing treatment options. Design Systematic review and network meta-analysis. Data sources Ovid Medline, Embase, and Cochrane Central up to 14 October 2022. Eligibility criteria for selecting studies Eligible randomised controlled trials compared drugs of interest in adults with type 2 diabetes. Eligible trials had a follow-up of 24 weeks or longer. Trials systematically comparing combinations of more than one drug treatment class with no drug, subgroup analyses of randomised controlled trials, and non-English language studies were deemed ineligible. Certainty of evidence was assessed following the GRADE (grading of recommendations, assessment, development and evaluation) approach. Results The analysis identified 816 trials with 471 038 patients, together evaluating 13 different drug classes; all subsequent estimates refer to the comparison with standard treatments. Sodium glucose cotransporter-2 (SGLT-2) inhibitors (odds ratio 0.88, 95% confidence interval 0.83 to 0.94; high certainty) and GLP-1 receptor agonists (0.88, 0.82 to 0.93; high certainty) reduce all cause death; non-steroidal mineralocorticoid receptor antagonists, so far tested only with finerenone in patients with chronic kidney disease, probably reduce mortality (0.89, 0.79 to 1.00; moderate certainty); other drugs may not. The study confirmed the benefits of SGLT-2 inhibitors and GLP-1 receptor agonists in reducing cardiovascular death, non-fatal myocardial infarction, admission to hospital for heart failure, and end stage kidney disease. Finerenone probably reduces admissions to hospital for heart failure and end stage kidney disease, and possibly cardiovascular death. Only GLP-1 receptor agonists reduce non-fatal stroke; SGLT-2 inhibitors are superior to other drugs in reducing end stage kidney disease. GLP-1 receptor agonists and probably SGLT-2 inhibitors and tirzepatide improve quality of life. Reported harms were largely specific to drug class (eg, genital infections with SGLT-2 inhibitors, severe gastrointestinal adverse events with tirzepatide and GLP-1 receptor agonists, hyperkalaemia leading to admission to hospital with finerenone). Tirzepatide probably results in the largest reduction in body weight (mean difference −8.57 kg; moderate certainty). Basal insulin (mean difference 2.15 kg; moderate certainty) and thiazolidinediones (mean difference 2.81 kg; moderate certainty) probably result in the largest increases in body weight. Absolute benefits of SGLT-2 inhibitors, GLP-1 receptor agonists, and finerenone vary in people with type 2 diabetes, depending on baseline risks for cardiovascular and kidney outcomes ( https://matchit.magicevidence.org/230125dist-diabetes ). Conclusions This network meta-analysis extends knowledge beyond confirming the substantial benefits with the use of SGLT-2 inhibitors and GLP-1 receptor agonists in reducing adverse cardiovascular and kidney outcomes and death by adding information on finerenone and tirzepatide. These findings highlight the need for continuous assessment of scientific progress to introduce cutting edge updates in clinical practice guidelines for people with type 2 diabetes. Systematic review registration PROSPERO CRD42022325948.
The results of our study suggest that glioblastoma patients may experience prolonged survival due to VPA administration. Sub-analysis confirmed the benefit of VPA use compared to a non-AEDs group and an other-AEDs group. Further RCTs of this subject should be performed.
Purpose. The purpose of this study was to compare the accuracy and clinical outcomes of the medial open wedge high tibial osteotomy (MOWHTO) using a three-dimensional (3D-) printed patient-specific instrumentation (PSI) with that of conventional surgical techniques. Methods. A prospective comparative study which included 18 patients who underwent MOWHTO using 3D-printed PSI technique (3D-printed group) and 19 patients with conventional technique was conducted from Jan 2019 to Dec 2019. After the preoperative planning, 3D-printed PSI (cutting guide model) was used in MOWHTO for 3D-printed group, while freehand osteotomies were adopted in the conventional group. The accuracy of MOWHTO for each method was compared using the radiological index obtained preoperatively and postoperatively, including mechanical femorotibial angle (mFTA) and medial mechanical proximal tibial angle (mMPTA), and correction error. Regular clinical outcomes were also compared between the 2 groups. Results. The correction errors in the 3D-printed group were significantly lower than the conventional group (mFTA, 0.2 ° ± 0.6 ° vs. 1.2 ° ± 1.4 ° , P = 0.004 ) (mMPTA, 0.1 ° ± 0.4 ° vs. 2.2 ° ± 1.8 ° , P < 0.00001 ). There was a significantly shorter duration ( P < 0.00001 ) and lower radiation exposures ( P < 0.00001 ) for the osteotomy procedure in the 3D-printed group than in the conventional group. There were significantly higher subjective IKDC scores ( P = 0.009 ) and Lysholm scores ( P = 0.03 ) in the 3D-printed group at the 3-month follow-up, but not significantly different at other time points. Fewer complications occurred in the 3D-printed group. Conclusions. With the assistance of the 3D-printed patient-specific cutting guide model, a safe and feasible MOWHTO can be conducted with superior accuracy than the conventional technique.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.